2024 Partners
Expertise Partners
Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence.
Our Cell & Gene offering spans across development and manufacturing services, products, solutions, testing and automation platforms as well as tools and technologies to enable you to develop, de-risk and industrialize your therapy, from basic research to commercialization.
Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multiomics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
Our licensed technologies include AAV development and transduction solutions from SIRION Biotech and Pin-Point base editing from Horizon Discovery - both now part of Revvity.
Industry Partners
GenixCure
GENIXCURE develops CARE TM, an AAV capsid engineering platform based on its machine learning engine called InsightMiner TM. The company also has its wholly owned therapeutic programs against ALS, FTD, and Lafora disease.
To the classical method of directed evolution of AAV, the company has added an AI arm by which we can find enhanced rAAV vectors in terms of transduction efficiency and de-targeting features. XOB-031, one of our own AAV vectors to CNS, has been adopted as a new cargo for GXC303(ALS) and GXC304(FTD).
Genixcure’s CARE TM is a wholly new AAV engineering platform featuring AI screening, providing unique value to sponsors developing programs in modality of AAV gene therapy.
Modalis Therapeutics
Modalis Therapeutics, founded in 2016 and listed on the Tokyo Stock Exchange, is a forerunner in the field of epigenetic medicine. Modalis’ proprietary CRISPR-GNDM® technology is capable of specifically modulating the expression of disease-relevant genes without introducing double-strand DNA breaks, which has been validated in disease animal models and non-human primates studies.
Specializing in genetic disorders affecting the neuromuscular and CNS regions, Modalis’s flagship program, MDL101, aims to treat LAMA2-CMD, a severe congenital form of muscular dystrophy to which no effective therapy exists
Sania Therapeutics
Sania Therapeutics is a pre-clinical stage biotechnology company based in London, UK. Sania’s goal is to develop highly targeted, safe and low dose gene therapies. With this approach we aim to build treatments for highly prevalent disorders, with millions of potential patients, in areas that have not previously been considered for advanced therapies.
Our proprietary capsid discovery platform, R-Scan recreates human neural circuits in an in vitro setting to maximise translatability into the clinic. This platform allows us to generate novel AAVs that are highly targeted to specific subtypes of neuron while showing minimal off-target transduction and biodistribution.
Exhibition Partners
Elegen
Elegen brings unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience in developing novel and scalable approaches in molecular biology, chemistry, and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area.
Event Partners
NanoMosaic LLC
Nanomosaic’s Tessie platform, for gene therapy applications, combines the ability to quantify proteins and nucleic acids in a single run, enabling the simultaneous detection and characterization of adeno-associated virus (AAV) capsids and therapeutic transgenes. With Tessie, researchers can characterize and quantify full, empty, partial, and internally deleted transgenes directly from crude extracts, providing them with the unique ability to accurately quantify the full and intact transgene throughout the bioprocessing and manufacturing of AAV therapies. The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
Recombinetics
Recombinetics is a leading company in livestock gene editing and applied technologies for biomedical research, gene therapy, regenerative medicine, and animal agriculture. As innovators and early adopters of molecular tools for animal gene editing, we’ve developed novel swine reporter models that activate permanent markers to track gene therapy delivery to any tissue or cell in vivo. With preclinical testing capabilities and the ability to deliver swine models with custom alleles, we are an integrated source for preclinical testing in engineered large animal models.
Virica Biotech
Virica develops cell enhancers that improve the yield and quality of vaccines , viral vector manufacturing, and cell and gene therapies, allowing developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by anti-viral defenses in manufacturing cells. Purpose formulated VSE combinations substantially increase manufacturing yields and reduce the cost of goods for a range of life-changing products, including vaccines, gene therapies, and cell therapies.
Media Partners
Gene Therapy Net
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network for the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.